Ropes & Gray endorses open market sale of $200M Zenas shares
Zenas BioPharma filed a supplemental legal opinion supporting the sale of up to $200 million in common stock under an existing open market agreement. This regulatory approval facilitates the continued liquidity program for the company's shares.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed